Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
- The Jefferies 2019
London Healthcare Conference onThursday, November 21, 2019 at3:20 p.m. Greenwich Mean Time (10:20 a.m. Eastern Time ) - The
Piper Jaffray 31st Annual Healthcare Conference inNew York onWednesday, December 4, 2019 at3:30 p.m. Eastern Time
A live webcast of each presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation.
About
Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Top-line data from the phase 3 pivotal efficacy trial (NODE-301) is expected in the middle of the first half of 2020.
Contact:
Argot Partners
212-600-1902
david@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-300957945.html
SOURCE